PA5-50644

antibody from Invitrogen Antibodies

Targeting: CALCRL CGRPR, CRLR

Western blot (Recommended by provider)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-50644

Provider

Invitrogen Antibodies

Product name

CALCRL Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

The antibody detects endogenous levels of total CALCRL / CRLR protein.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

2.7 mg/mL

Storage

-20°C

References

Submitted references

Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231(LUC+)).

Gutierrez S, Boada MD
Cancer cell international 2018;18:216

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 NP time-dependent induced changes in the expression of neurokinin and CGRP receptors in the MDA-MB-231 LUC+ cells homogenate using Western blot analysis. a Representative immunoblots for NK1R (~ 75-100 kDa), NK2R (~ 44 kDa), RAMP1 (~ 17 kDa), CALCRL (~ 45-55 kDa) and GAPDH (~ 37 kDa) from cells homogenates. b Changes in the expression of NK-1R, NK-2R, RAMP1 and CALCRL (first, second, third and fourth panel, respectively) in human metastatic breast cancer cells at 24-72 h after NP treatment. Three independent experiments were performed. Data represent NK-1R, NK-2R, RAMP1 and CALCRL/GAPDH ratio, normalized to the mean value for the corresponding control group at 24, 48 or 72 h (punctuated line). Data are presented as median (numbers and horizontal line) with boxes representing the 25 and 75 percentiles, * P < 0.05; ** P < 0.01; *** P < 0.001 compared to control or NP treatment group